You are here

gene therapy

On CAR-T’s Edge, Seattle Researchers Plot to Bypass Novartis Therapy

On CAR-T’s Edge, Seattle Researchers Plot to Bypass Novartis Therapy

Xconomy

Seattle Children's

pediatric cancer

Flag link:

Bidding war erupts over Dimension’s gene therapy pipeline as Ultragenyx counters Regenxbio deal

Bidding war erupts over Dimension’s gene therapy pipeline as Ultragenyx counters Regenxbio deal

Endpoints

Dimension Therapeutics

Flag link:

Profit finally in sight for gene therapy specialist Oxford Bio

Profit finally in sight for gene therapy specialist Oxford Bio

Yahoo/Reuters

Oxford BioMedica

Flag link:

Pfizer commits $100M for a gene therapies plant in North Carolina

Pfizer commits $100M for a gene therapies plant in North Carolina

Fierce Pharma

drug manufacturing

Flag link:

Is This Why bluebird bio Dipped 10.5% in July?

Is This Why bluebird bio Dipped 10.5% in July?

Motley Fool

Flag link:

bluebird bio Pauses During 2017 Data Blitz

bluebird bio Pauses During 2017 Data Blitz

Motley Fool

Flag link:

Spark offers a glimpse of efficacy in first two hemophilia A gene therapy patients

Spark offers a glimpse of efficacy in first two hemophilia A gene therapy patients

Endpoints

Spark Therapeutics

Flag link:

FDA embraces the first US application for a gene therapy, offering an accelerated test case

FDA embraces the first US application for a gene therapy, offering an accelerated test case

Endpoints

Spark Therapeutics

RPE65-mediated inherited retinal disease

Flag link:

BioMarin, Spark, raising the stakes for hemophilia

BioMarin, Spark, raising the stakes for hemophilia

BioPharma Dive

Spark Therapeutics

Flag link:

FDA panel to focus on safety of Novartis gene therapy drug

FDA panel to focus on safety of Novartis gene therapy drug

Yahoo/Reuters

advisory panels

acute lymphoblastic leukemia

Flag link:

Who will pay for CRISPR?

Who will pay for CRISPR?

Stat

Spark Therapeutics

Flag link:

Bluebird Reports Early Results From Upgraded Gene Therapy

Bluebird Reports Early Results From Upgraded Gene Therapy

Xconomy

clinical trials

beta-thalassemia

Flag link:

FDA to Clear Path for Drugs Aimed at Cancer-Causing Genes

FDA to Clear Path for Drugs Aimed at Cancer-Causing Genes

Bloomberg

tumor-agnostic therapies

Flag link:

Sarepta to collaborate with Genethon on DMD gene therapy; Chinese investors pull back on Pluristem investment

Sarepta to collaborate with Genethon on DMD gene therapy; Chinese investors pull back on Pluristem investment

Endpoints

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link:

5 Trends affecting gene therapy development

5 Trends affecting gene therapy development

BioPharma Dive

drug development

Flag link:

Pfizer expands gene therapy effort on hemophilia, bagging rights to a Sangamo drug in a $545M deal

Pfizer expands gene therapy effort on hemophilia, bagging rights to a Sangamo drug in a $545M deal

Endpoints

Sangamo BioSciences

Flag link:

Biotech firm pulls pioneering gene therapy due to no demand

Biotech firm pulls pioneering gene therapy due to no demand

Yahoo/Reuters

Flag link:

Icahn hires on gene therapy legend—and big biotech disruptor—Richard Mulligan as Bristol-Myers rumors simmer

Icahn hires on gene therapy legend—and big biotech disruptor—Richard Mulligan as Bristol-Myers rumors simmer

Endpoints

Richard Mulligan

Bristol-Myers Squibb

Flag link:

Why Spark's CEO says 2017 may be a 'historic year' for his gene therapy company

Why Spark's CEO says 2017 may be a 'historic year' for his gene therapy company

Bizjournals.com

Spark Therapeutics

Jeffrey D. Marrazzo

Flag link:

Biotech Renova takes over Janssen's rights to heart failure candidate stresscopin

Biotech Renova takes over Janssen's rights to heart failure candidate stresscopin

Fierce Biotech

Renova Therapeutics

Flag link: